Cargando…

Safety and immunogenicity of an MF59™-adjuvanted subunit influenza vaccine in elderly Chinese subjects

BACKGROUND: The safety and immunogenicity of an MF59™-adjuvanted subunit influenza vaccine (Sub/MF59™; FLUAD(®), Novartis Vaccines) was evaluated among elderly Chinese subjects (≥ 60 years of age). After a preliminary Phase I, open-label study (n = 25) to assess safety 1–14 days post-vaccination, a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Rongcheng, Fang, Hanhua, Li, Yanping, Liu, Youping, Pellegrini, Michele, Podda, Audino
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2291031/ https://www.ncbi.nlm.nih.gov/pubmed/18289372 http://dx.doi.org/10.1186/1742-4933-5-2

Ejemplares similares

MF59(®)‐adjuvanted vaccines for seasonal and pandemic influenza prophylaxis
por: Banzhoff, Angelika, et al.
Publicado: (2008)

Safety of MF59-Adjuvanted Influenza Vaccination in the Elderly: Results of a Comparative Study of MF59-Adjuvanted Vaccine Versus Nonadjuvanted Influenza Vaccine in Northern Italy
por: Villa, Marco, et al.
Publicado: (2013)

AS03- and MF59-Adjuvanted Influenza Vaccines in Children
por: Wilkins, Amanda L., et al.
Publicado: (2017)

MF59(®)-Adjuvanted H5N1 Vaccine Induces Immunologic Memory and Heterotypic Antibody Responses in Non-Elderly and Elderly Adults
por: Banzhoff, Angelika, et al.
Publicado: (2009)

Fluad®-MF59®-Adjuvanted Influenza Vaccine in Older Adults
por: Tsai, Theodore F
Publicado: (2013)

Correction: MF59(®)-Adjuvanted H5N1 Vaccine Induces Immunologic Memory and Heterotypic Antibody Responses in Non-Elderly and Elderly Adults
por: Banzhoff, Angelika, et al.
Publicado: (2009)

Immunogenicity of standard, high-dose, MF59-adjuvanted, and recombinant-HA seasonal influenza vaccination in older adults
por: Li, Athena P. Y., et al.
Publicado: (2021)

Safety and Immunogenicity of MF59-Adjuvanted Cell Culture–Derived A/H5N1 Subunit Influenza Virus Vaccine: Dose-Finding Clinical Trials in Adults and the Elderly
por: Frey, Sharon E, et al.
Publicado: (2019)

Immunogenicity and protective efficacy in dogs of an MF59™-adjuvanted vaccine against recombinant canine/porcine coronavirus
por: Decaro, Nicola, et al.
Publicado: (2011)

Enhanced passive safety surveillance of the MF59-adjuvanted quadrivalent influenza vaccine in the elderly during the 2021/22 influenza season
por: Amicizia, Daniela, et al.
Publicado: (2023)

Effectiveness, immunogenicity, and safety of influenza vaccines with MF59 adjuvant in healthy people of different age groups: A systematic review and meta-analysis
por: Yang, Jing, et al.
Publicado: (2020)

Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50–64 Years of Age
por: Poder, Airi, et al.
Publicado: (2023)

Memory-like innate response to booster vaccination with MF-59 adjuvanted influenza vaccine in children
por: Kazmin, Dmitri, et al.
Publicado: (2023)

Intranasal Immunization Using Mannatide as a Novel Adjuvant for an Inactivated Influenza Vaccine and Its Adjuvant Effect Compared with MF59
por: Ren, Shu-Ting, et al.
Publicado: (2017)

Relative Effectiveness of MF59 Adjuvanted Trivalent Influenza Vaccine vs Nonadjuvanted Vaccines During the 2019–2020 Influenza Season
por: Imran, Mahrukh, et al.
Publicado: (2022)

Phase 4, Post-Marketing Safety Surveillance of the MF59-Adjuvanted Influenza Vaccines FLUAD(®) and VANTAFLU(®) in South Korean Subjects Aged ≥65 Years
por: Yoo, Byung Wook, et al.
Publicado: (2018)

The Cost-Effectiveness of Vaccination of Older Adults with an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Other Available Quadrivalent Vaccines in Germany
por: Kohli, Michele A., et al.
Publicado: (2022)

Effectiveness of MF59™ Adjuvanted Influenza A(H1N1)pdm09 Vaccine in Risk Groups in the Netherlands
por: Wijnans, Leonoor, et al.
Publicado: (2013)

Immunogenicity and Safety of an MF59-adjuvanted Quadrivalent Seasonal Influenza Vaccine in Young Children at High Risk of Influenza-associated Complications: A Phase III, Randomized, Observer-blind, Multicenter Clinical Trial
por: Esposito, Susanna, et al.
Publicado: (2020)

The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination
por: Goll, Johannes B., et al.
Publicado: (2022)

Influenza A/H1N1 MF59 adjuvanted vaccine in pregnant women and adverse perinatal outcomes: multicentre study
por: Rubinstein, F, et al.
Publicado: (2013)

A Caprine Herpesvirus 1 Vaccine Adjuvanted with MF59™ Protects against Vaginal Infection and Interferes with the Establishment of Latency in Goats
por: Marinaro, Mariarosaria, et al.
Publicado: (2012)

The safety and immunogenicity of a MF59-adjuvanted H5N1 prepandemic influenza vaccine in healthy adults primed with homologous or heterologous H5N1 vaccines: an observational study
por: Wei, Sung-Hsi, et al.
Publicado: (2014)

Vaccine adjuvant MF59 promotes the intranodal differentiation of antigen-loaded and activated monocyte-derived dendritic cells
por: Cioncada, Rossella, et al.
Publicado: (2017)

Letter to editor regarding the systematic review and meta‐analysis by Coleman et al. on the effectiveness of MF59‐adjuvanted seasonal influenza vaccine in older adults
por: Yin, J. Kevin, et al.
Publicado: (2021)

MF59-adjuvanted influenza vaccine (FLUAD®) elicits higher immune responses than a non-adjuvanted influenza vaccine (Fluzone®): A randomized, multicenter, Phase III pediatric trial in Mexico
por: Cruz-Valdez, Aurelio, et al.
Publicado: (2018)

Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial
por: Chappell, Keith J, et al.
Publicado: (2021)

Additional Burden Averted in the United States From Use of MF59-Adjuvanted Seasonal Influenza Vaccine Compared With Standard Seasonal Influenza Vaccine Among Adults ≥65 Years
por: McGovern, Ian, et al.
Publicado: (2023)

Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein
por: Hosseinipour, Mina C, et al.
Publicado: (2020)

Longevity of protective immune responses induced by a split influenza A (H7N9) vaccine mixed with MF59 adjuvant in BALB/c mice
por: Ou, Huilin, et al.
Publicado: (2017)

Effectiveness of the MF59‐adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age or older, a systematic review and meta‐analysis
por: Coleman, Brenda L., et al.
Publicado: (2021)

Cost-Effectiveness of Vaccination of Older Adults with an MF59(®)-Adjuvanted Quadrivalent Influenza Vaccine Compared to Standard-Dose and High-Dose Vaccines in Denmark, Norway, and Sweden
por: Jacob, Jorge, et al.
Publicado: (2023)

Effectiveness of a MF-59™-adjuvanted pandemic influenza vaccine to prevent 2009 A/H1N1 influenza-related hospitalisation; a matched case-control study
por: Steens, Anneke, et al.
Publicado: (2011)

Preclinical evaluation of the safety and pathogenicity of a live attenuated recombinant influenza A/H7N9 seed strain and corresponding MF59-adjuvanted split vaccine
por: Ou, Huilin, et al.
Publicado: (2016)

Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial
por: Griffiths, Paul D, et al.
Publicado: (2011)

A novel atheroprotective role of MF59-like adjuvant when co-administered with CETP vaccine in rabbit model of atherosclerosis
por: Aghebati, Tamara, et al.
Publicado: (2016)

2490. A Phase 1, Randomized, Observer Blind, Antigen and Adjuvant Dosage Finding Study to Evaluate the Safety and Immunogenicity of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects ≥65 Years of Age
por: Otten, Gillis, et al.
Publicado: (2018)

Analysis of the safety and immunogenicity profile of an azoximer bromide polymer-adjuvanted subunit influenza vaccine.
por: Kompier, Ronald, et al.
Publicado: (2022)

Antibody responses to intradermal or intramuscular MF59-adjuvanted influenza vaccines as evaluated in elderly institutionalized volunteers during a season of partial mismatching between vaccine and circulating A(H3N2) strains
por: Camilloni, Barbara, et al.
Publicado: (2014)

Enhanced Passive Safety Surveillance (EPSS) confirms an optimal safety profile of the use of MF59(®)‐adjuvanted influenza vaccine in older adults: Results from three consecutive seasons
por: Panatto, Donatella, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_j9iimhpdijua6qhhvti3gs5e7p